In order to improve patient outcomes, fuel research and ultimately help to provide more treatment options and modalities for the brain cancer patient, EndBrainCancer Initiative (EBCI) relies on donors, sponsors, grants and Corporate Partners. Our Corporate Partners understand the vital importance of providing IMMEDIATE ACCESS to free patient services and programs to the brain tumor community through our “Direct Connect” personalized, one-on-one programs as well as our Education/Awareness/Outreach programs. Our Corporate Partners are committed to helping us keep our services and programs free to the brain tumor community and to the general public as well as in allowing the team at EBCI to help make the brain tumor community aware of all treatment options, studies and clinical trials that may be available for brain tumor patients. To learn more about clinical trials you may be a candidate for, please contact Delores Kannas, EBCI’s Clinical Research Nurse & Patient Navigator, at 425-444-2215 M-TH 9:30a-3:30p pst or via our Patient/Caregiver Inquiry Form HERE. You may also reach us via email at [email protected] If you would like to discuss becoming an EBCI Corporate Partner please click HERE, complete the form to the right, or contact us at 425-444-2215 & [email protected] 
__________________________________________________________________________________________________________________________________________________
The TRIDENT study is for patients recently diagnosed with glioblastoma (GBM). This clinical trial is evaluating the safety and efficacy of Tumor Treating Fields (TTFields) delivered by the Optune® treatment paired with radiation therapy and temozolomide in newly diagnosed GBM patients [About TTFields].
All patients participating in this study will receive Optune® treatment [The TRIDENT Trial].
Novocure maintains this website to help patients get basic information about the study.
If you want to take part in the TRIDENT trial, please contact one of the participating centers [TRIDENT Centers] as soon as possible. Consult your treating physician if you have questions about your medical condition and if a clinical trial is right for you.
ELIGIBILITY
Inclusion Criteria*
- Histologically confirmed diagnosis of GBM according to WHO classification criteria.
- Age ≥ 22 years in US and Age ≥ 18 years in Ex-US
- Recovered from maximal debulking surgery, if applicable (gross total resection, partial resection, and biopsy-only patients are all acceptable)
- Planned treatment with RT/TMZ followed by TTFields and maintenance TMZ (150-200 mg/m2 daily x 5 d, q28 days)
- Karnofsky performance status ≥ 70
- Life expectancy ≥ least 3 months
For more information please visit: https://novocuretrials.com/trial/trident/
__________________________________________________________________________________________________________________________________________________
Novocure began with a patient-forward approach that continues to drive their mission today. With more than 20 years of research and many significant milestones, they have established themselves as an innovator in oncology dedicated to improving the lives of cancer patients. Novocure launched Optune® – their Tumor Treating Fields delivery system for glioblastoma (GBM) – in the United States for the treatment of recurrent glioblastoma in 2011. In October 2015, they received U.S. Food and Drug Administration (FDA) approval to market and sell Optune for the treatment of adult patients with newly diagnosed GBM in combination with temozolomide. Their currently active markets include United States, Germany, Austria, Switzerland, Sweden, Israel and Japan.
- The science of Tumor Treating Fields has the potential to extend beyond GBM. They have six ongoing or completed phase 2 pilot trials for brain metastases, non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer, liver cancer and mesothelioma.
- They presented their phase 2 pilot data in pancreatic and ovarian cancers at their research and development day on Dec. 12, 2016.
- In 2016, they began their phase 3 pivotal trial in brain metastases originating from NSCLC. In 2017, they started their phase 3 pivotal trials in NSCLC and pancreatic cancer.
- In 2019, they initiated our phase 3 pivotal trial in recurrent, platinum-resistant ovarian cancer. Internationally, more than 20 institutions are studying the effects of Tumor Treating Fields in cancer treatment.
__________________________________________________________________________________________________________________________________________________ 
With Agios, people living with cancer and rare genetic diseases are at the center of everything they do and every decision they make. They are guided by a deep-rooted commitment to creating treatment options that make a meaningful difference in patients’ lives and fundamentally change the way cancer and rare genetic diseases are treated. At Agios, their focus is on people and culture which comes from OSOP (Other Side of Possible) philosophy where employees are empowered to work together to accomplish something extraordinary while keeping the patient at the center of every decision they make. To learn more about their Commitment to Patients, Investigational Medicines, Clinical Trials, IDH Mutations in Cancer, Pyruvate Kinase Deficiency, various Patient Resources, and a list of their Medicines; please visit them at www.agios.com for more information. Agios is now studying a new investigational drug in the fight against low-grade gliomas!
site can provide information and guidance to help you discuss next steps with your doctor. For more information click HERE or call our Direct Connect Services at 425.444.2215.__________________________________________________________________________________________________________________________________________________
The Genesis of GT Medical Technologies and GammaTile Therapy
For decades, clinicians have sought better treatment options for patients with brain tumors. To overcome the limitations of current treatments and raise the standard of care, a group of brain tumor specialists joined forces to address this critical, unmet need and elevate the Standard of Care for patients with brain tumors.
GT Medical Technologies, creators of GammaTile Therapy, is dedicated to improving the lives of patients with brain tumors. GammaTile is an FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) for patients with newly diagnosed malignant and recurrent brain tumors including primary and metastatic tumors. GammaTile is the most recently FDA-cleared device for treating treat brain tumors. Visit GT Medical Technologies website HERE. How GammaTile Therapy Works The small, bioresorbable GammaTile is placed directly at the site of the tumor after the tumor is surgically removed, providing immediate radiation treatment to remaining tumor cells before they can replicate. Because the therapy is implanted at the end of surgery, patients treated with GammaTile Therapy require no additional trips to the hospital or clinic for radiation therapy. GammaTile is designed to limit side effects, including hair loss. For more information click HERE or call our Direct Connect Services at 425.444.2215. 
Benefits
- Delays brain tumor recurrence, potentially extending survival
- Facilitates favorable reimbursement (CMS craniotomy code ICD-10 MS-DRG 023)
- Integrates into the surgical flow with an approximately 5-minute placement for procedural ease and speed
-
Enables patients with brain tumors to receive radiation treatment while going about their daily lives